Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Down 5.9% in January

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) saw a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 11,090,000 shares, a decrease of 5.9% from the January 15th total of 11,790,000 shares. Based on an average trading volume of 1,470,000 shares, the days-to-cover ratio is presently 7.5 days.

Aquestive Therapeutics Trading Down 3.8 %

AQST stock traded down $0.12 during midday trading on Wednesday, hitting $3.03. The stock had a trading volume of 2,207,584 shares, compared to its average volume of 1,870,711. The firm has a market capitalization of $276.28 million, a price-to-earnings ratio of -6.73 and a beta of 2.67. Aquestive Therapeutics has a 52 week low of $2.24 and a 52 week high of $6.23. The stock has a 50-day simple moving average of $3.29 and a 200 day simple moving average of $4.18.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on AQST shares. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Friday, December 20th. Cantor Fitzgerald started coverage on Aquestive Therapeutics in a research report on Tuesday, December 17th. They issued an "overweight" rating and a $17.00 price objective for the company. Finally, Leerink Partners increased their price objective on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an "outperform" rating in a research report on Friday, October 25th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $11.00.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of AQST. nVerses Capital LLC acquired a new position in Aquestive Therapeutics during the third quarter worth $28,000. New York State Common Retirement Fund raised its stake in Aquestive Therapeutics by 713.3% during the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company's stock worth $43,000 after acquiring an additional 10,700 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Aquestive Therapeutics during the fourth quarter worth $44,000. Two Sigma Advisers LP acquired a new position in Aquestive Therapeutics during the fourth quarter worth $57,000. Finally, PKS Advisory Services LLC acquired a new position in Aquestive Therapeutics during the fourth quarter worth $63,000. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.